Infection Prevention and Antimicrobial Stewardship Program Collaboration During the COVID-19 Pandemic: a Window of Opportunity.
Antimicrobial stewardship
COVID-19
Coronavirus disease 2019
Infection prevention
SARS-CoV-2
Journal
Current infectious disease reports
ISSN: 1523-3847
Titre abrégé: Curr Infect Dis Rep
Pays: United States
ID NLM: 100888983
Informations de publication
Date de publication:
2021
2021
Historique:
accepted:
13
07
2021
entrez:
24
8
2021
pubmed:
25
8
2021
medline:
25
8
2021
Statut:
ppublish
Résumé
We describe the similarities between antimicrobial stewardship programs (ASPs) and infection prevention programs (IPPs), and we discuss how these similarities lend themselves to synergy between programs. We also discuss how the COVID-19 pandemic has generated further opportunities for future collaborations that could benefit both programs. The COVID-19 pandemic has created new needs, such as real-time data and access to personnel important to both programs, such as information technologists and infectious diseases specialists. It has also increased concerns about rising rates of antimicrobial resistance and healthcare-associated infections, both of which overlap significantly and are key focus areas for both ASPs and IPPs. These emergent issues have highlighted the need for enhanced program infrastructure and new team models. The shift towards telecommunication and telework has facilitated the creation of enhanced infrastructures for collaboration on activities ranging from data access and reporting to providing telehealth services to remote hospitals. These enhanced infrastructures can be leveraged in future collaborative efforts between ASPs and IPPs. Collaboration between IPPs and ASPs can mitigate setbacks experienced by health systems during the current pandemic, enhance the performance of both programs in the post-pandemic era and increase their preparedness for future pandemic threats. As health systems plan for the post-pandemic era, they should invest in opportunities for synergy between ASPs and IPPs highlighted during the pandemic.
Identifiants
pubmed: 34426728
doi: 10.1007/s11908-021-00759-w
pii: 759
pmc: PMC8374122
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
15Informations de copyright
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.
Déclaration de conflit d'intérêts
Conflict of InterestMariam Assi, Salma Abbas, Priya Nori, Michelle Doll, Emily Godbout, Gonzalo Bearman, and Michael P. Stevens declare that they have no conflicts of interest.
Références
Infect Control Hosp Epidemiol. 2020 Jun;41(6):744-745
pubmed: 32167442
Lancet Infect Dis. 2017 Sep;17(9):990-1001
pubmed: 28629876
Am J Infect Control. 2021 Aug;49(8):1072-1074
pubmed: 33524453
J Antimicrob Chemother. 2020 Nov 1;75(11):3386-3390
pubmed: 32766706
Open Forum Infect Dis. 2017 Jul 20;4(3):ofx117
pubmed: 28748196
Clin Microbiol Rev. 2011 Jan;24(1):141-73
pubmed: 21233510
Infect Control Hosp Epidemiol. 2018 Apr;39(4):467-472
pubmed: 29576043
Future Microbiol. 2016;11(1):93-102
pubmed: 26323589
Clin Infect Dis. 2007 Sep 1;45 Suppl 2:S112-21
pubmed: 17683015
Infect Control Hosp Epidemiol. 2022 Jan;43(1):26-31
pubmed: 33602361
Curr Infect Dis Rep. 2020;22(9):23
pubmed: 32834785
Med Clin North Am. 2018 Sep;102(5):873-882
pubmed: 30126577
Jt Comm Perspect. 2016 Jul;36(7):1, 3-4, 8
pubmed: 27548932